SynthesisFrontiers in medicine2025
Psychiatric symptoms and syndromes in sarcoidosis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcoidosis is often associated with psychiatric symptoms and syndromes (PSS). This systematic review and meta-analysis aimed to summarize available literature on the prevalence of PSS in sarcoidosis, as well as their potential associations. Methods: A systematic search was conducted across PubMed, including case reports and studies that investigated PSS in sarcoidosis. A meta-analysis was performed on studies that assessed the association between sarcoidosis and PSS, using odds ratios (OR). Results: We included 43 studies and 53 cases on PSS in patients with sarcoidosis. The weighted average prevalence was 24.9% for depression, 28.7% for anxiety, 29.2% for neurocognitive symptoms, 54.4% for fatigue, 50.5% for excessive daytime sleepiness and 26.9% for sleep disturbances and insomnia, with the best available evidence for depression, anxiety and fatigue. The meta-analysis ( Conclusion: Sarcoidosis is associated with a higher prevalence of PSS. Nonetheless research in this area remains limited. Systematic use of standardized psychiatric assessment tools is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.